查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403526

2030 年肝病诊断市场预测：按疾病类型、技术、最终用户和地区进行的全球分析

Liver Disease Diagnostics Market Forecasts to 2030 - Global Analysis By Disease Type (Viral Hepatitis, Alcoholic Liver Disease, Non-alcoholic Fatty Liver Disease, Liver Cancer and Other Disease Types), Technique, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肝病诊断市场规模为 403.2 亿美元，预计预测期内复合年增长率为 8.1%，到 2030 年将达到 695.4 亿美元。

肝病诊断剂对于各种肝臟相关疾病的诊断和治疗至关重要。这些诊断包括旨在评估肝臟健康、识别异常并确定肝臟疾病的根本原因的各种程序和影像方式。此外，测量肝酵素水平（例如丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST））的血液检查以及评估某些抗体或病毒标记物是否存在的测试也是常用的诊断工具。

根据世界卫生组织（WHO）2022年6月发布的报告，全球整体估计有5,800万人感染慢性C型肝炎病毒，每年新增感染者约150万人。

提高认识和筛检工作

随着非营利组织和医疗保健组织宣传活动提高了公众对肝病严重性的认识，肝病诊断的需求量很大。此外，由于针对高风险族群（例如有吸毒史的人群或具有某些易患肝病的人口特征的人群）的积极筛检计划，早期诊断正在增加。除了减轻医疗保健系统的负担之外，对预防医学的关注和认识的提高也使人们有能力透过定期检查来控制肝臟健康。

先进诊断的成本过高

主要障碍是尖端肝病诊断的成本，包括先进的影像方式和分子测试。总成本由高昂的初始投资、持续的维护成本以及专业培训的需求决定。此外，这些经济障碍阻碍了这些诊断技术的广泛使用以及患者和医疗机构等的使用。

个体化医疗的发展

由于个人化医疗的变化，肝病诊断市场存在重大机会。透过根据患者的基因组成、生活方式选择和疾病特异性特征来客製化诊断策略，可以使肝病的诊断和治疗更加准确。此外，基因组学和分子分析的进步使得有针对性的诊断工具的创建成为可能，为更有效率和客製化的患者照护打开了大门。

合规和监管问题

肝病诊断市场正面临着更严格和动态的法规环境的威胁。公司面临时间和资源方面的挑战，因为他们必须遵守合规性要求、获得必要的核准并应对复杂的监管流程，这也可能会延迟产品发布。然而，对于市场参与企业而言，违规会带来严重风险，包括法律问题、市场退出和监管后果。

COVID-19 的影响：

肝病诊断市场受到了 COVID-19 大流行的严重影响。大流行造成的全球破坏包括关闭、医疗保健系统负担过重、重新调整资源来对抗病毒、暂时减少选择性手术和例行就诊的数量，以及减少整体诊断服务的需求。此外，由于研发计划的延误、供应链中断和医疗保健优先事项的转变，市场参与企业面临挑战。此次疫情凸显了强大诊断能力的重要性，加速了远端医疗和远端监控解决方案的采用。

非酒精性脂肪肝（NAFLD）预计将成为预测期内最大的部分

非酒精性脂肪肝疾病（NAFLD）预计将占据最大份额。随着肥胖和代谢症候群变得越来越普遍，非酒精性脂肪肝 (NAFLD) 已成为世界上慢性肝病的主要原因。此外，NAFLD（从轻度肝脂肪变性到非酒精性脂肪性肝炎（NASH）等严重）盛行率不断上升，正在推动这一领域的主导地位。因此，对肝病诊断的需求显着增加，包括使用最先进的影像方式和血液检测来准确诊断和分期 NAFLD。

研究机构部门预计在预测期内复合年增长率最高

预测期内复合年增长率最高的领域是研究机构。研究机构对于促进诊断设备和程序开发的创新和技术进步至关重要。该领域的强劲成长得益于对转化研究、生物标记发现和创新诊断技术开发的日益关注。此外，研究机构还与诊断公司和医疗保健提供者合作进行临床研究、检验诊断测定并主导新型​​诊断技术的开发。政府津贴和资助正在推动研究机构产业不断发展，研究活动活性化。

比最大的地区

预计北美将占据最大的市场占有率。鼓励创新的强有力的法规环境、高额医疗保健支出、技术进步和完善的医疗保健基础设施是该地区占据主导地位的部分原因。此外，由于存在重要的市场参与者和研究机构，以及积极实施先进诊断技术，北美在肝病诊断市场占据主导地位。

复合年增长率最高的地区：

医疗诊断市场预计将以亚太地区最高的复合年增长率成长。这是由于该地区人口不断增长、慢性病发病率不断上升、公众对早期疾病检测的意识不断增强，以及对医疗基础设施的大量投资。快速成长主要归功于中阶的不断壮大、政府为改善医疗保健服务所做的努力，以及中国等国家和医疗保健领域的技术进步。此外，由于亚太地区的动态性和对实施尖端诊断解决方案的专注，亚太地区在医疗保健诊断行业的强劲成长中处于有利地位。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肝病诊断市场：依疾病类型

  • 病毒性肝炎
  • 酒精性肝臟疾病
  • 非酒精性脂肪肝（NAFLD）
  • 肝癌
  • 其他类型的疾病

第六章全球肝病诊断市场：依技术分类

  • 内视镜检查
  • 切片检查
  • 成像技术
    • 超音波
    • MRI
    • 电脑断层扫描
  • 临床检查
    • 验血
    • 肝功能检查
    • 基因检测
  • 其他技术

第七章全球肝病诊断市场：依最终使用者分类

  • 医院
  • 实验室
  • 研究机构
  • 其他最终用户

第八章全球肝病诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Abbott Laboratories
  • Horiba Medical
  • F. Hoffmann-La Roche Ltd.
  • Cosara Diagnostics Pvt Ltd
  • Laboratory Corporation of America Holdings
  • Bio-Rad Laboratories Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Fujifilm Corporation
  • PerkinElmer
  • Biosino Bio-Technology and Science Inc
  • Quest Diagnostics Incorporated
  • Trivitron Healthcare
  • Boston Scientific Corporation
  • Qiagen NV
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc
  • Randox Laboratories Ltd.
Product Code: SMRC24751

According to Stratistics MRC, the Global Liver Disease Diagnostics Market is accounted for $40.32 billion in 2023 and is expected to reach $69.54 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Diagnostics for liver diseases are essential for determining and treating a wide range of liver-related conditions. These diagnostics include a variety of procedures and imaging methods designed to evaluate the liver's health, identify anomalies, and identify the underlying causes of liver diseases. Moreover, blood tests to measure liver enzyme levels, such as alanine transaminase (ALT) and aspartate transaminase (AST), as well as tests to assess the presence of particular antibodies or viral markers, are commonly used diagnostic tools.

According to report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.

Market Dynamics:

Driver:

Growing consciousness and screening initiatives

Liver disease diagnostics are in high demand due to growing public awareness of the seriousness of liver diseases, which has been fueled by campaigns from non-profits and healthcare groups. Additionally, early-stage diagnoses are increasing as a result of proactive screening programs, which typically target high-risk populations such as those with a history of substance abuse or particular demographics predisposed to liver disorders. In addition to lessening the strain on healthcare systems, this increased focus and awareness of preventive healthcare also give people the power to take control of their liver health through routine screenings.

Restraint:

Exorbitant expense of advanced diagnosis

A major barrier is the expense of cutting-edge liver disease diagnostics, which include sophisticated imaging methods and molecular testing. The total cost is influenced by a high initial investment, ongoing maintenance expenses, and the requirement for specialized training. Furthermore, this financial obstacle prevents these diagnostics from being widely used and made accessible to patients and healthcare organizations alike.

Opportunity:

Developments in customized medicine

There is a large opportunity for the liver disease diagnostics market due to the changing face of personalized medicine. Liver disease diagnosis and treatment can be made more accurate by customizing diagnostic strategies based on a person's genetic composition, lifestyle choices, and unique disease features. Moreover, the creation of targeted diagnostic tools is made possible by developments in genomics and molecular profiling, which open the door to more efficient and customized patient care.

Threat:

Issues with compliance and regulatory difficulties

The market for liver disease diagnostics is threatened by stricter and more dynamic regulatory environments. Companies face difficulties in terms of time, resources, and possible delays in product launches when they must follow compliance requirements, secure required approvals, and navigate complex regulatory processes. However, for market participants, non-compliance poses a serious risk of legal problems, market withdrawals, or restrictions.

COVID-19 Impact:

The market for liver disease diagnostics has been significantly impacted by the COVID-19 pandemic. The pandemic's worldwide disruption, which included lockdowns, overburdened healthcare systems, and the redirection of resources to fight the virus, temporarily, reduced the number of elective surgeries and routine medical visits, which had an impact on the demand for diagnostic services as a whole. Additionally, market participants faced difficulties due to delays in R&D projects, interruptions in the supply chain, and changes in healthcare priorities. Positively, the pandemic accelerated the adoption of tele-health and remote monitoring solutions by highlighting the significance of strong diagnostic capabilities.

The Non-alcoholic Fatty Liver Disease (NAFLD) segment is expected to be the largest during the forecast period

The non-alcoholic fatty liver disease (NAFLD) segment is anticipated to hold the largest share. Since obesity and metabolic syndrome are becoming more common, non-alcoholic fatty liver disease (NAFLD) has emerged as a major global cause of chronic liver disease. Furthermore, the rising prevalence of NAFLD, which can vary from mild hepatic steatosis to more serious illnesses like non-alcoholic steatohepatitis (NASH), is what drives the segment's dominance. Because of this, there has been a noticeable increase in the need for liver disease diagnostics, such as cutting-edge imaging methods and blood tests for precise NAFLD diagnosis and staging.

The Research Institutes segment is expected to have the highest CAGR during the forecast period

The segment with the highest CAGR during the estimation period is research institutes. Research institutes are essential for fostering innovation and technical progress in the development of diagnostic instruments and procedures. The robust growth of this segment can be attributed to the growing emphasis on translational research, biomarker discovery, and the development of innovative diagnostic technologies. Moreover, research institutes conduct clinical studies, validate diagnostic assays, and lead the way in developing novel diagnostic techniques in partnership with diagnostic companies and healthcare providers. Government grants and funding, along with the increased volume of research activity, are driving the Research Institutes sector forward.

Region with largest share:

North America is expected to hold the largest market share. A strong regulatory environment that encourages innovation, high healthcare spending, technological advancements, and a well-established healthcare infrastructure are some of the reasons for the region's dominance. Additionally, North America holds a dominant position in the liver disease diagnostics market due in part to the existence of important market players, research institutions, and a proactive approach towards adopting advanced diagnostic technologies.

Region with highest CAGR:

The healthcare diagnostics market is expected to grow at the highest CAGR in the Asia-Pacific region. The region's expanding population, the rising frequency of chronic diseases, the increased public awareness of early disease detection, and the significant investments made in healthcare infrastructure are all contributing factors to this. The rapid growth is mostly being driven by middle-class population expansion, government initiatives to increase healthcare accessibility, and technological advancements in countries like China and India. Furthermore, the Asia-Pacific region is well-positioned for strong growth in the healthcare diagnostics industry due to its dynamic nature and emphasis on implementing cutting-edge diagnostic solutions.

Key players in the market:

Some of the key players in Liver Disease Diagnostics market include Abbott Laboratories, Horiba Medical, F. Hoffmann-La Roche Ltd., Cosara Diagnostics Pvt Ltd, Laboratory Corporation of America Holdings, Bio-Rad Laboratories Inc., Meril Life Sciences Pvt. Ltd., Fujifilm Corporation, PerkinElmer, Biosino Bio-Technology and Science Inc, Quest Diagnostics Incorporated, Trivitron Healthcare, Boston Scientific Corporation, Qiagen N.V, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc and Randox Laboratories Ltd.

Key Developments:

In December 2023, F. Hoffmann-La Roche Ltd. announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In August 2022, HORIBA, one of the global leaders in a wide range of medical diagnostic equipment, and SigTuple, a medtech company that develops AI-powered digital microscopy solutions, announced today a partnership to accelerate adoption of SigTuple's AI100 across the Indian subcontinent. HORIBA, a medical diagnostic company, and SigTuple, a MedTech company, on Monday, announced a partnership to accelerate the adoption of SigTuple's AI100 across the Indian subcontinent.

Disease Types Covered:

  • Viral Hepatitis
  • Alcoholic Liver Disease
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Liver Cancer
  • Other Disease Types

Techniques Covered:

  • Endoscopy
  • Biopsy
  • Imaging Techniques
  • Laboratory Tests
  • Other Techniques

End Users Covered:

  • Hospitals
  • Laboratories
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liver Disease Diagnostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Viral Hepatitis
  • 5.3 Alcoholic Liver Disease
  • 5.4 Non-alcoholic Fatty Liver Disease (NAFLD)
  • 5.5 Liver Cancer
  • 5.6 Other Disease Types

6 Global Liver Disease Diagnostics Market, By Technique

  • 6.1 Introduction
  • 6.2 Endoscopy
  • 6.3 Biopsy
  • 6.4 Imaging Techniques
    • 6.4.1 Ultrasound
    • 6.4.2 MRI
    • 6.4.3 CT Scan
  • 6.5 Laboratory Tests
    • 6.5.1 Blood Tests
    • 6.5.2 Liver Function Tests
    • 6.5.3 Genetic Tests
  • 6.6 Other Techniques

7 Global Liver Disease Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Laboratories
  • 7.4 Research Institutes
  • 7.5 Other End Users

8 Global Liver Disease Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Horiba Medical
  • 10.3 F. Hoffmann-La Roche Ltd.
  • 10.4 Cosara Diagnostics Pvt Ltd
  • 10.5 Laboratory Corporation of America Holdings
  • 10.6 Bio-Rad Laboratories Inc.
  • 10.7 Meril Life Sciences Pvt. Ltd.
  • 10.8 Fujifilm Corporation
  • 10.9 PerkinElmer
  • 10.10 Biosino Bio-Technology and Science Inc
  • 10.11 Quest Diagnostics Incorporated
  • 10.12 Trivitron Healthcare
  • 10.13 Boston Scientific Corporation
  • 10.14 Qiagen N.V
  • 10.15 Siemens Healthcare GmbH
  • 10.16 Thermo Fisher Scientific Inc
  • 10.17 Randox Laboratories Ltd.

List of Tables

  • Table 1 Global Liver Disease Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 4 Global Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 5 Global Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 6 Global Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 7 Global Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 8 Global Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 9 Global Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 10 Global Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 11 Global Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 12 Global Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 13 Global Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 14 Global Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 15 Global Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 16 Global Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 17 Global Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 18 Global Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 19 Global Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 20 Global Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 22 Global Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 23 Global Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 24 Global Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 25 North America Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 North America Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 27 North America Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 28 North America Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 29 North America Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 30 North America Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 31 North America Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 32 North America Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 33 North America Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 34 North America Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 35 North America Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 36 North America Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 37 North America Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 38 North America Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 39 North America Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 40 North America Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 41 North America Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 42 North America Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 43 North America Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 44 North America Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 45 North America Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 47 North America Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 48 North America Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Europe Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Europe Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 51 Europe Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 52 Europe Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 53 Europe Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 54 Europe Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 55 Europe Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 56 Europe Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 57 Europe Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 58 Europe Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 59 Europe Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 60 Europe Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 61 Europe Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 62 Europe Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 63 Europe Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 64 Europe Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 65 Europe Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 66 Europe Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 67 Europe Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 68 Europe Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 69 Europe Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 70 Europe Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 71 Europe Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 72 Europe Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 73 Asia Pacific Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 Asia Pacific Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 75 Asia Pacific Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 76 Asia Pacific Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 77 Asia Pacific Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 78 Asia Pacific Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 79 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 80 Asia Pacific Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 81 Asia Pacific Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 82 Asia Pacific Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 83 Asia Pacific Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 84 Asia Pacific Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 85 Asia Pacific Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 86 Asia Pacific Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 87 Asia Pacific Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 88 Asia Pacific Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 89 Asia Pacific Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 90 Asia Pacific Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 91 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 92 Asia Pacific Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 93 Asia Pacific Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 94 Asia Pacific Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 95 Asia Pacific Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 96 Asia Pacific Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 97 South America Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 98 South America Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 99 South America Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 100 South America Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 101 South America Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 102 South America Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 103 South America Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 104 South America Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 105 South America Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 106 South America Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 107 South America Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 108 South America Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 109 South America Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 110 South America Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 111 South America Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 112 South America Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 113 South America Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 114 South America Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 115 South America Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 116 South America Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 117 South America Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 118 South America Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 119 South America Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 120 South America Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 121 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 122 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 123 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Viral Hepatitis (2021-2030) ($MN)
  • Table 124 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Alcoholic Liver Disease (2021-2030) ($MN)
  • Table 125 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Non-alcoholic Fatty Liver Disease (NAFLD) (2021-2030) ($MN)
  • Table 126 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 127 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 128 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Technique (2021-2030) ($MN)
  • Table 129 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Endoscopy (2021-2030) ($MN)
  • Table 130 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 131 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Imaging Techniques (2021-2030) ($MN)
  • Table 132 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 133 Middle East & Africa Liver Disease Diagnostics Market Outlook, By MRI (2021-2030) ($MN)
  • Table 134 Middle East & Africa Liver Disease Diagnostics Market Outlook, By CT Scan (2021-2030) ($MN)
  • Table 135 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Laboratory Tests (2021-2030) ($MN)
  • Table 136 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 137 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 138 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Genetic Tests (2021-2030) ($MN)
  • Table 139 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other Techniques (2021-2030) ($MN)
  • Table 140 Middle East & Africa Liver Disease Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 141 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 142 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Laboratories (2021-2030) ($MN)
  • Table 143 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 144 Middle East & Africa Liver Disease Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)